ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

10 links0 made here, not in the record19 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06564844A Phase III, RandomisedStudy of Adjuvant Dato-DXdin Combination WithRilvegostomig orRilvegostomig MonotherapyVersus Standard of Care,Following Complete TumourAstraZenecaPhase 3 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionAdenocarcinomaThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDRUGSDatopotamab deruxtecanIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedRilvegostomigIntervention entry›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCarboplatinIntervention entry›Nov 3 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorCisplatinIntervention entry›Nov 3 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorEtoposideIntervention entry›Nov 3 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorPemetrexedIntervention entry›Nov 3 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorVinorelbineIntervention entry›Nov 3 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorTegafur-uracilEntry “UFT”, read by our name rule›Nov 3 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Datopotamab deruxtecan

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Datopotamab Deruxtecan”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 3Datopotamab deruxtecanClaude Opus 5.5TestedCurrent
Nov 3RilvegostomigClaude Opus 5.5TestedCurrent
Nov 3CarboplatinClaude Opus 5.5ComparatorCurrent
Nov 3CisplatinClaude Opus 5.5ComparatorCurrent
Nov 3EtoposideClaude Opus 5.5ComparatorCurrent
Nov 3PemetrexedClaude Opus 5.5ComparatorCurrent
Nov 3VinorelbineClaude Opus 5.5ComparatorCurrent
Nov 3Tegafur-uracilClaude Opus 5.5ComparatorCurrent
Nov 14Carcinoma, Non-Small-Cell LungRule based · condition-kind ruleFinest filed termCurrent
Nov 14AdenocarcinomaRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18Datopotamab deruxtecanRule based · role ruleTestedAgrees
Nov 18RilvegostomigRule based · role ruleTestedAgrees
Nov 18CarboplatinRule based · role ruleComparatorAgrees
Nov 18CisplatinRule based · role ruleComparatorAgrees
Nov 18EtoposideRule based · role ruleComparatorAgrees
Nov 18PemetrexedRule based · role ruleComparatorAgrees
Nov 18VinorelbineRule based · role ruleComparatorAgrees
Nov 18Tegafur-uracilRule based · role ruleComparatorAgrees
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.